This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mieke M. Hulshof, MD; Stan Pavel, MD, PhD; Ferdinand C. Breedveld, MD, PhD; Ben A. C. Dijkmans, MD, PhD; Bert Jan Vermeer, MD, PhD

Arch Dermatol. 1994;130(10):1290-1293.

Abstract
Background
None of the commonly used drugs for the treatment of scleroderma appears to significantly influence the fibrotic stage of this disorder. Recently, a beneficial effect of the treatment with oral calcitriol (1,25 dihydroxyvitamin D3) in 10 patients with systemic sclerosis and four patients with morphea was described. This fact could be ascribed to the immunoregulatory effects of calcitriol observed in vitro and to inhibition of fibroblast growth. We treated three patients with extensive morphea with remarkable results.

Observation
Three patients with generalized morphea were treated with calcitriol in an oral daily dose of 0.50 to 0.75 µg. After 3 to 7 months of treatment, the mobility of the joints improved and the skin extensibility increased. No adverse effects were observed. The improvement persisted after discontinuation of therapy during a follow-up period of 1 to 2 years.

Conclusion
Calcitriol showed a beneficial effect in generalized morphea during an open study. Double-blind, placebo-controlled trials are needed to assess its therapeutic value.

(Arch Dermatol. 1994;130:1290-1293)

Author Affiliations
From the Department of Dermatology (Drs Hulshof, Pavel, and Vermeer) and Rheumatology (Drs Breedveld and Dijkmans), University Hospital Leiden, the Netherlands.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil
Martini et al.
Rheumatology (Oxford) 2009;48:1410-1413.
ABSTRACT | FULL TEXT  

Treatment of Scleroderma
Sapadin and Fleischmajer
Arch Dermatol 2002;138:99-105.
ABSTRACT | FULL TEXT  

PUVA Bath Photochemotherapy for Localized Scleroderma: Evaluation of 17 Consecutive Patients
Kerscher et al.
Arch Dermatol 1996;132:1280-1282.
ABSTRACT  

Oral Calcitriol as a New Therapeutic Agent in Localized and Systemic Scleroderma
Humbert et al.
Arch Dermatol 1995;131:850-851.
ABSTRACT